Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trial
European Heart Journal - Cardiovascular Pharmacotherapy · 2025
DOI: 10.1093/ehjcvp/pvae080 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2025. Verfasst von Usman Baber und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA. Hauptthemen laut MEDLINE: Ticagrelor, Percutaneous Coronary Intervention, Aspirin, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Icahn School of Medicine at Mount Sinai, AstraZeneca.
Abstract (Originalsprache)
Aims
In standard time-to-first event analysis, early aspirin discontinuation followed by ticagrelor monotherapy has been shown to reduce bleeding without increasing ischaemic complications compared with ticagrelor plus aspirin after percutaneous coronary intervention (PCI). We evaluated whether these treatment effects are preserved when recurrent events are considered. Methods and results In this TWILIGHT trial post-hoc analysis, we assessed the effects of ticagrelor monotherapy on the total number of events that occurred over the 12-month follow-up among 7119 high-risk patients randomized to aspirin or placebo in addition to ticagrelor at 3 months post-PCI if event-free and adherent to treatment. There were 391 patients with at least one Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding (primary endpoint). Of those, 28 (7.2%) had a recurrent event. The total number of BARC 2, 3, or 5 bleeding events was 148 in the ticagrelor monotherapy arm compared with 278 with ticagrelor plus aspirin arm (P < 0.001). Among 272 patients with at least one key secondary ischaemic endpoint (all-cause death, myocardial infarction, or stroke), 37 (13.6%) sustained a recurrent event. Total ischaemic events were similar (155 vs. 159) in the two groups.
Conclusion
Among selected high-risk patients who underwent PCI and completed 3 months of dual antiplatelet therapy followed by ticagrelor with or without aspirin, recurrent bleeding was less common than recurrent ischaemic events over 12 months. Analysis of total events indicates that ticagrelor monotherapy continues to be more effective than ticagrelor plus aspirin in reducing bleeding without a signal of ischaemic harm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, NY 10029, USA.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI 20090, Italy.
- Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
- Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL 32209, USA.
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.
ORCID-Profile: Usman Baber, Davide Cao, Timothy Collier, Samantha Sartori, Birgit Vogel, Vijay Kunadian, Carlo Briguori, David J Cohen, Robert Gil, Kurt Huber, Javier Escaned, Richard Shlofmitz, Roxana Mehran
Förderung
- Icahn School of Medicine at Mount Sinai
- AstraZeneca
Zitieren
APA
Baber, U., Cao, D., Collier, T., Sartori, S., Dangas, G., Angiolillo, D. J., Vogel, B., Kunadian, V., Briguori, C., Cohen, D. J., Dudek, D., Gibson, C. M., Gil, R., Huber, K., Kaul, U., Kornowski, R., Krucoff, M. W., Mehta, S., Moliterno, D. J., …, & Mehran, R. (2025). Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trial. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvae080
Vancouver
Baber U, Cao D, Collier T, Sartori S, Dangas G, Angiolillo DJ, et al. Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trial. European Heart Journal - Cardiovascular Pharmacotherapy. 2025. doi:10.1093/ehjcvp/pvae080
BibTeX
@article{Baber2025,
author = {Baber, Usman and Cao, Davide and Collier, Timothy and Sartori, Samantha and Dangas, George and Angiolillo, Dominick J and Vogel, Birgit and Kunadian, Vijay and Briguori, Carlo and Cohen, David J and Dudek, Dariusz and Gibson, C Michael and Gil, Robert and Huber, Kurt and Kaul, Upendra and Kornowski, Ran and Krucoff, Mitchell W and Mehta, Shamir and Moliterno, David J and Ohman, E Magnus and Escaned, Javier and Sardella, Gennaro and Sharma, Samin K and Shlofmitz, Richard and Weisz, Giora and Witzenbichler, Bernhard and Steg, P Gabriel and Pocock, Stuart and Mehran, Roxana},
title = {Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trial},
journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
year = {2025},
doi = {10.1093/ehjcvp/pvae080}
}
EUVIMED